Clinical Trial

Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus

Study acronym: PhagoPied
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for diabetic foot ulcers monoinfected by methicillin-resistant or susceptible S. aureus (MRSA or MSSA) as measured by the relative reduction in wound surface area (%) at 12 weeks.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2016-01-22; most recent amendment 2026-03-18.
Trial Details
NCT Number NCT02664740
Lead Sponsor Centre Hospitalier Universitaire de Nīmes
Collaborators: Phagenix
Conditions Diabetic Foot, Staphylococcal Infections
Enrollment 60 participants
Start Date 2026-09-01
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-20